Rowland & Co. Investment Counsel ADV grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,413 shares of the biopharmaceutical company’s stock after purchasing an additional 790 shares during the period. Rowland & Co. Investment Counsel ADV’s holdings in Gilead Sciences were worth $776,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of GILD. S&CO Inc. lifted its stake in shares of Gilead Sciences by 5.5% during the 4th quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock worth $396,000 after acquiring an additional 330 shares during the last quarter. Addenda Capital Inc. lifted its stake in shares of Gilead Sciences by 2.3% during the 4th quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock worth $3,735,000 after acquiring an additional 1,362 shares during the last quarter. IMA Wealth Inc. lifted its stake in shares of Gilead Sciences by 31.6% during the 4th quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 1,710 shares during the last quarter. Clear Perspective Advisors LLC lifted its stake in shares of Gilead Sciences by 3.6% during the 4th quarter. Clear Perspective Advisors LLC now owns 8,680 shares of the biopharmaceutical company’s stock worth $543,000 after acquiring an additional 300 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Gilead Sciences by 199,789.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after acquiring an additional 31,335,030 shares during the last quarter. 78.23% of the stock is owned by institutional investors and hedge funds.
In other news, Director Gayle E. Wilson sold 19,068 shares of Gilead Sciences stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the transaction, the director now directly owns 143,567 shares in the company, valued at approximately $9,630,474.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.16% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the business posted $1.78 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 6.23 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.84%. Gilead Sciences’s dividend payout ratio (DPR) is currently 37.07%.
A number of equities research analysts recently issued reports on the company. Wells Fargo & Co lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $95.00 to $68.00 in a research note on Monday, February 11th. Guggenheim started coverage on Gilead Sciences in a research report on Monday, December 17th. They set a “buy” rating and a $86.00 target price for the company. Raymond James set a $90.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, February 5th. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, December 4th. Finally, Citigroup lowered Gilead Sciences from a “buy” rating to a “neutral” rating and decreased their target price for the company from $100.00 to $75.00 in a research report on Tuesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $82.29.
TRADEMARK VIOLATION NOTICE: This story was first reported by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2019/03/17/rowland-co-investment-counsel-adv-has-776000-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Why are percentage gainers important?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.